Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 27;10(11):R293-R304.
doi: 10.1530/EC-21-0294.

Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack

Affiliations
Review

Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack

João Castro-Teles et al. Endocr Connect. .

Abstract

Objective: Pheochromocytomas are a hallmark feature of von Hippel-Lindau disease (vHL). To our knowledge, this is the first systematic review with meta-analysis evaluating the frequency of pheochromocytomas and/or paragangliomas (PPGLs) in patients with vHL, as well as among patients with different vHL subtypes.

Design: Systematic review with meta-analysis.

Methods: We searched on MEDLINE, Scopus, and Web of Science. We included primary studies assessing participants with vHL and reporting on the frequency of PPGL. We performed random-effects meta-analysis to quantitatively assess the frequency of PPGL, followed by meta-regression and subgroup analysis. Risk of bias analysis was performed to assess primary studies' methodological quality.

Results: We included 80 primary studies. In 4263 patients with vHL, the pooled frequency of PPGL was 19.4% (95% CI = 15.9-23.6%, I2 = 86.1%). The frequency increased to 60.0% in patients with vHL type 2 (95% CI = 53.4-66.3%, I2 = 54.6%) and was determined to be of 58.2% in patients with vHL type 2A (95% CI = 49.7-66.3%, I2 = 36.2%), compared to 49.8% in vHL type 2B (95% CI = 39.9-59.7%, I2 = 42.7%), and 84.1% in vHL type 2C (95% CI = 75.1-93.1%, I2 = 0%). In meta-regression analysis, more recent studies were associated with a higher frequency of PPGL. All studies had at least one internal validity item classified as 'high risk of bias,' with 13% studies having low risk of bias in all external validity items.

Conclusions: PPGLs are a common manifestation of vHL. Despite methodological limitations and differences across primary studies, our results point to the importance of PPGL screening in patients with vHL.

Keywords: frequency; paraganglioma; pheochromocytoma; systematic; von Hippel–Lindau.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram illustrating study selection process.
Figure 2
Figure 2
Risk of bias graph depicting the assessment of the methodological quality of included primary studies. Risk of study bias items assessed: aStudy’s target population as a close representation of the vHL national population. bSampling frame as a true or close representation of the target population. cSample selection based on a random/consecutive process. dLikelihood of nonresponse bias. eAcceptable case definition used in the study. fSame mode of evaluation for all subjects. gNumerator and denominator appropriate.

Similar articles

Cited by

References

    1. Choyke PL Glenn GM Walther MM Patronas NJ Linehan WM & Zbar B. Von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995194629–642. (10.1148/radiology.194.3.7862955) - DOI - PubMed
    1. Binderup MLM Galanakis M Budtz-Jorgensen E Kosteljanetz M & Bisgaard ML. Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark. European Journal of Human Genetics 201725301–307. (10.1038/ejhg.2016.173) - DOI - PMC - PubMed
    1. Wachtel H & Fishbein L. Genetics of pheochromocytoma and paraganglioma. Current Opinion in Endocrinology, Diabetes, and Obesity 202128283–290. (10.1097/MED.0000000000000634) - DOI - PubMed
    1. Juhlin CC.. Challenges in paragangliomas and pheochromocytomas: from histology to molecular immunohistochemistry. Endocrine Pathology 202132228–244. (10.1007/s12022-021-09675-0) - DOI - PMC - PubMed
    1. Prasad R Johnston LB Savage MO Martin L Perry LA & Storr HL. Pediatric endocrine screening for von Hippel-Lindau disease: benefits and the challenge of compliance. Journal of Endocrinological Investigation 201134296–299. (10.1007/BF03347089) - DOI - PubMed

LinkOut - more resources